Neumora logomark
Skip to main content

Our Pipeline

We are building a broad pipeline of novel precision medicines each with a targeted approach

Neuro-psychiatry

Neuro-degeneration

Pan-CNS

Target

Indication

Discovery

Preclinical

Phase 1

Phase 2

NMRA-140

KOR Antagonist

" >

Target

NMRA-140

KOR Antagonist

Major Depressive Disorder, Anhedonia

NMRA-511

V1aR Antagonist

" >

Target

NMRA-511

V1aR Antagonist

Anxiety Disorders

Target

NMRA-094

H1/5HT2a

Sleep Disorders

NMRA-CK1δ

CK1δ

" >

Target

NMRA-CK1δ

CK1δ

Neurodegenerative Diseases

NMRA-GCase

GCase

" >

Target

NMRA-GCase

GCase

Neurodegenerative Diseases

Target

NMRA-NLRP3

NLRP3

Neurodegenerative Diseases

NMRA-GRIN2A

GRIN2A

" >

Target

NMRA-GRIN2A

GRIN2A

Neuropsychiatric Disorders

NMRA-GRIN2B

GRIN2B

" >

Target

NMRA-GRIN2B

GRIN2B

Neuropsychiatric Disorders